Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

Konopleva, Marina; A. Pollyea, Daniel; Potluri, Jalaja; Chyla, Brenda; J. Hogdal, Leah; Busman, Todd; McKeegan, Evelyn; Hamed Salem, Ahmed; Zhu, Ming; L. Ricker, Justin; Blum, William; D. DiNardo, Courtney; M. Kadia, Tapan; Dunbar, Martin; Kirby, Rachel; Falotico, Nancy; D. Leverson, Joel; Humerickhouse, Rod; Mabry, Mack; M. Stone, Richard; M. Kantarjian, Hagop; Letai, Anthony

doi:10.1158/2159-8290.cd-16-0313

Public

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

Published in Cancer Discovery • Aug 12, 2016

Authors:

Marina Konopleva

Daniel A. Pollyea

Jalaja Potluri

Abstract

We present a phase II, single-arm study evaluating 800 mg daily venetoclax, a highly selective, oral small-molecule B-cell leukemia/lymphoma-2 (BCL2) inhibitor in patients with high-risk relapsed/refractory acute myelogenous leukemia (AML) or unfit for intensive chemotherapy. Responses were evaluate...

Subject

Venetoclax

Leukemia

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!